Among 13 NR pathways tested, agonists of pregnane X receptor (PXR, rifampicin, SR12813, and T-0907317), RAR (ATRA), and RXR (9-cis-retinoic acid) were able to increase the expression of hOCT1 in KCL22 cells and/or peripheral blood mononuclear cells from CML patients [107], suggesting that PXR, RAR, and RXR signaling pathways can be novel combinational partners for TKIs in therapeutic regimens. This evidence concerns the gene RARA and chronic myelogenous leukemia, BCR-ABL1 positive.